Reply to ‘Results of conservative management for consecutive esotropia after intermittent exotropia surgery’ – (Eye 29, 1626 (December 2015))
Reply to ‘Results of conservative management for consecutive esotropia after intermittent exotropia surgery’ Eye 29, 1626 (December 2015). doi:10.1038/eye.2015.149 Authors: D W Kim, S Y Han, U S Kim & S-H Baek
Comment on ‘The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ – (Eye 29, 1627 (December 2015))
Comment on ‘The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ Eye 29, 1627 (December 2015). doi:10.1038/eye.2015.168 Author: M Rodríguez-Vallejo
Response to: ‘Comment on The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ – (Eye 29, 1628 (December 2015))
Response to: ‘Comment on The Eye Phone Study: reliability and accuracy of assessing Snellen visual acuity using smartphone technology’ Eye 29, 1628 (December 2015). doi:10.1038/eye.2015.169 Authors: C Perera & R Chakrabarti
Comment on ‘Failure of intravitreal bevacizumab in the treatment of choroidal metastasis’ – (Eye 29, 1628 (December 2015))
Comment on ‘Failure of intravitreal bevacizumab in the treatment of choroidal metastasis’ Eye 29, 1628 (December 2015). doi:10.1038/eye.2015.174 Authors: H R Kourie, J Antoun & J Kattan
Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration of systemic therapy – (Eye 29, 1629 (December 2015))
Intravitreal bevacizumab for choroidal metastases: the key to efficacy is simultaneous administration of systemic therapy Eye 29, 1629 (December 2015). doi:10.1038/eye.2015.176 Authors: N Singh, R Bansal, D Behera & A Gupta